New drug cocktail aims to shrink rare head and neck melanoma before surgery
NCT ID NCT07353073
Summary
This study is testing a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before and after surgery for a rare type of head and neck melanoma. The goal is to see if this approach can shrink tumors effectively and safely before they are surgically removed. The trial will enroll about 30 adults with this specific, resectable cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
Conditions
Explore the condition pages connected to this study.